Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
FOCUS DIAGNOSTICS, INC.
SEEGENE

Genetic Errors Identified in 12 Major Cancer Types

By Labmedica International staff writers
Posted on 07 Nov 2013
Image: Immunohistochemistry of paraffin-embedded human ovary tumor using P53 antibody (Photo courtesy of Proteintech).
Image: Immunohistochemistry of paraffin-embedded human ovary tumor using P53 antibody (Photo courtesy of Proteintech).
The latest sequencing and analysis methods have been used to identify somatic variants across thousands of tumors, and 127 significantly mutated genes were detected.

Some of the same genes commonly mutated in certain cancers also occur in seemingly unrelated tumors. For example, a gene mutated in 25% of leukemia cases in the study also was found in tumors of the breast, rectum, head and neck, kidney, lung, ovary and uterus.

Scientists at the Washington University School of Medicine (St. Louis, MO, USA) performed exome sequencing on thousands of tumor samples and matched normal tissues, the latter being used as controls to distinguish somatic mutations from inherited variants. The teams analyzed the genes from 3,281 tumors, a collection of cancers of the breast, uterus, head and neck, colon and rectum, bladder, kidney, ovary, lung, brain and blood. In addition to finding common links among genes in different cancers, the scientists also identified a number of mutations exclusive to particular cancer types.

While the average number of mutated genes in tumors varied among the cancer types, most tumors had only two to six mutations in genes that drive cancer. This may be one reason why cancer is so common. Genes that have a significant effect on survival were also identified. These included tumor protein p53 (TP53), an already well-known cancer gene, occurred most commonly across the different tumor types. It was found in 42% of samples and routinely was associated with a poor prognosis, particularly in kidney cancer, head and neck cancer and acute myeloid leukemia. Another gene, Breast Cancer 1 (BRCA1) associated protein-1 (ubiquitin carboxy-terminal hydrolase) (BAP1), was also linked with an unfavorable prognosis, especially in patients with kidney and uterine cancer.

These discoveries set the stage for devising new diagnostic tools and more personalized cancer treatments. Li Ding, PhD, the senior author of the study, said, “Because we now know, for example, that genes mutated in leukemia also can be altered in breast cancer and that genetic errors in lung cancer also can show up in colon and rectal cancer, we think one inclusive diagnostic test that includes all cancer genes would be ideal. This would provide a more complete picture of what's going on in a tumor, and that information could be used to make decisions about treatment.” The study was published on October 16, 2013, in the journal Nature.

Related Links:

Washington University School of Medicine



GREINER-BIO-ONE
PURITAN MEDICAL
ADVANCED INSTRUMENTS
BioConferenceLive

Channels

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more

Industry News

view channel

Roche Acquires IQuum, Strengthens Diagnostics Offerings with Unique System

The acquisition by Roche (Basel, Switzerland) of IQuum, Inc. (Marlborough, MA, USA) will enable Roche to more quickly enter the point-of-care (POC) segment of molecular diagnostics with products based on IQuum proprietary lab-in-tube technology. The technology underlies a novel biological sample testing platform that enables... Read more
 

Events

26 Apr 2014 - 30 Apr 2014
Copyright © 2000-2014 Globetech Media. All rights reserved.